Expand REGN Menu
REGN MENU

REGN Latest Press Releases

-- February 4, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN PRNewswire 3:05 PM
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 12:00 PM
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights REGN Globe Newswire 11:57 AM
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals Globe Newswire 11:47 AM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PRNewswire 8:11 AM
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion Globe Newswire 6:30 AM
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PRNewswire 5:45 AM

-- February 3, 2025 --

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 6:08 PM
Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion Globe Newswire 4:55 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions Globe Newswire 12:00 PM
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights REGN Globe Newswire 11:20 AM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 9:11 AM
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN PRNewswire 5:45 AM

-- January 31, 2025 --

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PRNewswire 5:50 PM
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 3:56 PM
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 12:00 PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN PRNewswire 5:45 AM

-- January 30, 2025 --

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PRNewswire 6:12 PM
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join Contact Levi & Korsinsky Globe Newswire 12:42 PM
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 11:11 AM
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PRNewswire 5:45 AM

-- January 29, 2025 --

Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN) Hagens Berman Globe Newswire 4:47 PM
The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline Globe Newswire 12:45 PM
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit PRNewswire 11:33 AM
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals Globe Newswire 10:57 AM

-- January 28, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN PRNewswire 10:00 PM
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 9:02 PM
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Globe Newswire 12:00 PM
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PRNewswire 5:45 AM

-- January 27, 2025 --

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PRNewswire 5:07 PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit REGN Globe Newswire 1:18 PM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PRNewswire 10:40 AM
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN) Hagens Berman Globe Newswire 8:22 AM
Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) PRNewswire 5:45 AM

-- January 26, 2025 --

REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit Globe Newswire 10:15 AM

-- January 25, 2025 --

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 8:51 AM

-- January 24, 2025 --

DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 2:01 PM
DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions Globe Newswire 12:00 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 10:30 AM
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PRNewswire 5:45 AM

-- January 23, 2025 --

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PRNewswire 3:01 PM
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search PRNewswire 12:02 PM
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search Globe Newswire 12:00 PM
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 12:00 PM
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PRNewswire 5:45 AM

-- January 22, 2025 --

Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action PRNewswire 8:16 PM
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 6:30 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 1:39 PM
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Globe Newswire 1:08 PM
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action Contact Levi & Korsinsky to Learn More Globe Newswire 12:51 PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals Globe Newswire 11:32 AM

-- January 21, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN PRNewswire 5:50 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 4:00 PM
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations Investors Should Contact The Gross Law Firm for More Information REGN Globe Newswire 12:36 PM
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 12:00 PM
INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline Globe Newswire 8:33 AM
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 6:09 AM
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PRNewswire 5:45 AM

-- January 20, 2025 --

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 4:00 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 2:56 PM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm PRNewswire 10:55 AM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PRNewswire 9:00 AM
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PRNewswire 5:45 AM

-- January 18, 2025 --

REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit Globe Newswire 8:55 AM

-- January 17, 2025 --

Robbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, Inc Globe Newswire 5:20 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 12:38 PM
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 12:00 PM
NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline Globe Newswire 8:33 AM
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN PRNewswire 5:45 AM

-- January 16, 2025 --

ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action REGN Globe Newswire 9:02 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights REGN Globe Newswire 2:00 PM
DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions Globe Newswire 12:00 PM
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 11:27 AM
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 9:28 AM
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN PRNewswire 5:45 AM

-- January 15, 2025 --

Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 2:10 PM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit PRNewswire 1:48 PM
The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline REGN Globe Newswire 12:48 PM
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Globe Newswire 12:05 PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals PRNewswire 10:34 AM

-- January 14, 2025 --

Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights Business Wire 7:16 PM
REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:05 PM
Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith Business Wire 12:00 PM
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN PRNewswire 5:45 AM

-- January 13, 2025 --

REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc. Globe Newswire 9:48 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 4:00 PM
ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit PRNewswire 3:44 PM
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery Contact Levi & Korsinsky Globe Newswire 12:13 PM
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Business Wire 12:00 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 10:42 AM
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 6:30 AM
Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial Globe Newswire 6:15 AM
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery Globe Newswire 6:05 AM
REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 5:48 AM
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN PRNewswire 5:45 AM

-- January 12, 2025 --

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 4:00 PM

-- January 10, 2025 --

REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Business Wire 9:30 PM
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel Globe Newswire 5:55 PM
Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action Business Wire 2:49 PM
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PRNewswire 2:25 PM
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 12:09 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 8:38 AM

-- January 9, 2025 --

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 4:00 PM
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman PRNewswire 2:25 PM

-- January 8, 2025 --

Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman Globe Newswire 9:29 PM
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm Business Wire 7:30 PM
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit Globe Newswire 6:38 PM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Globe Newswire 6:11 PM
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Globe Newswire 5:07 PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals Business Wire 4:39 PM
Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action Business Wire 2:53 PM
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights Globe Newswire 12:55 PM

-- January 7, 2025 --

REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors Business Wire 10:00 PM
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025 Globe Newswire 4:05 PM

-- December 19, 2024 --

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results Globe Newswire 7:00 AM

-- December 17, 2024 --

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM
EYLEA HD (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion Globe Newswire 7:00 AM

-- December 16, 2024 --

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year Globe Newswire 4:30 PM

-- December 9, 2024 --

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma Globe Newswire 5:45 PM

-- December 7, 2024 --

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab Globe Newswire 7:00 PM

-- December 6, 2024 --

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors PRNewswire 12:00 PM

-- December 4, 2024 --

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Globe Newswire 1:00 PM

-- December 3, 2024 --

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Globe Newswire 12:33 PM

-- December 2, 2024 --

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors PRNewswire 12:00 PM

-- November 27, 2024 --

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 4:00 PM

-- November 26, 2024 --

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 12:00 PM

-- November 25, 2024 --

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Globe Newswire 12:00 PM

-- November 15, 2024 --

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Globe Newswire 1:00 AM
Dupixent (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) Globe Newswire 12:59 AM

-- November 13, 2024 --

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH Globe Newswire 7:00 AM

-- November 11, 2024 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- November 6, 2024 --

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Globe Newswire 1:00 AM
Dupixent (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Globe Newswire 1:00 AM

-- November 4, 2024 --

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 3:00 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 1:24 PM

-- November 1, 2024 --

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 3:44 PM

-- October 31, 2024 --

Regeneron Reports Third Quarter 2024 Financial and Operating Results Globe Newswire 6:30 AM

-- October 24, 2024 --

Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI Globe Newswire 8:00 AM
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Globe Newswire 8:00 AM

-- October 18, 2024 --

Three-year Results for EYLEA HD (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema Globe Newswire 5:05 PM

-- September 27, 2024 --

Dupixent (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD Globe Newswire 9:35 AM
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Globe Newswire 9:35 AM
Dupixent (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Globe Newswire 7:00 AM
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD Globe Newswire 7:00 AM

-- September 26, 2024 --

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 Globe Newswire 4:05 PM

-- September 20, 2024 --

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Globe Newswire 7:45 AM
Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old Globe Newswire 7:45 AM

-- September 13, 2024 --

Dupixent (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Globe Newswire 12:15 PM

-- September 11, 2024 --

EYLEA HD (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile Globe Newswire 7:00 AM
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Globe Newswire 1:05 AM
Dupixent (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) Globe Newswire 1:04 AM
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Globe Newswire 1:00 AM
Dupixent (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial Globe Newswire 12:59 AM

-- September 9, 2024 --

Libtayo (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer Globe Newswire 5:00 PM
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO Globe Newswire 7:00 AM